Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.

Blood - 12 Jun 2014

Cazzola Mario, Kralovics Robert

Abstract excerpt

Our understanding of the genetic basis of myeloproliferative neoplasms began in 2005, when the JAK2 (V617F) mutation was identified in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2 exon 12 and MPL exon 10 mutations were then detected in subsets of patients, and subclonal driver mutations in other genes were found to be associated with disease progression. Recently, somatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Neoplasms
Share to Calreticulin
Share to Genetic Heterogeneity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Receptors, Thrombopoietin

Share to World Health Organization

Source

Identifiers

PMID: 24786775
DOI: 10.1182/blood-2014-03-530865

Genes

JAK2
MPL
CALR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.PMID 24786775Read ↗

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Semantic proximity Read ↗

Calreticulin Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.Semantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Somatic mutations of calreticulin in myeloproliferative neoplasms.Semantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Mutant Calreticulin in the Myeloproliferative NeoplasmsSemantic proximity Read ↗

The Calreticulin gene and myeloproliferative neoplasms.Semantic proximity Read ↗

Calreticulin exon 9 mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Frequency and Molecular Characteristics of Calreticulin Gene (CALR) Mutations in Patients with JAK2-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Calreticulin mutations in essential thrombocythemia and primary myelofibrosis.Semantic proximity Read ↗

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.